Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 7, 2012, Pages 1125-1136

  Muñoz, Patricia ^a   Paris, Irmgard ^a,b   Sanders, Laurie H ^c   Greenamyre, J Timothy ^c   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD SANTO TOMÁS   (Chile)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aminochrome; Dopamine; DT diaphorase; Neuromelanin; Parkinson's disease; VMAT 2

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINOCHROME; DOPAMINE; LOBELINE; NEUROTOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESERPINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; ENZYME ACTIVITY; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SUBSTANTIA NIGRA; TRANSMISSION ELECTRON MICROSCOPY;

ANALYSIS OF VARIANCE; ANIMALS; CELL DEATH; CELL LINE; DNA; DOPAMINE; HUMANS; INDOLEQUINONES; LOBELINE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIA; NAD(P)H DEHYDROGENASE (QUINONE); NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, INBRED F344; RESERPINE; SUBSTANTIA NIGRA; TRANSFECTION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 84860341994     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.03.010     Document Type: Article

References (55)

1. Chaudhry F., Edwards R., Fonnum F. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substance. Annu. Rev. Pharmacol. Toxicol. 2008, 48:277-301.
2. Knoth J., Zallakian M., Njus D. Stoichiometry of H+-linked dopamine transport in chromaffin granule ghost. Biochemistry 1981, 206:625-6629.
3. Guillot T.S., Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 2009, 39:149-170.
4. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., Youdim M.B. Dopamine 6-hydroxydopamine iron and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1996, 1316:160-168.
5. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
6. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., Tampellini D. The absolute concentration of nigral neuromelanin assayed by a new sensitive method increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 2002, 510:216-220.
7. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., Giaveri G., Arosio P., Santambrogio P., Fariello R.G., Karatekin E., Kleinman M.H., Turro N., Hornykiewicz O., Zucca F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9843-9848.
8. Kastner A., Hirsch E.C., Lejeune O., Javoy-Agid F., Rascol O., Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J. Neurochem. 1992, 59:1080-1089.
9. Gibb W.R. Melanin tyrosine hydroxylase calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 1992, 581:283-291.
10. Conway K., Rochet J.C., Bieganski R.M., Lansbury P.T. Kinetic stabilization of the α-synuclein adducts. Science 2001, 294:1346-1349.
11. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280:21212-21219.
12. Van Laar V.S., Mishizen A.J., Cascio M., Hastings T.G. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 2009, 34:487-500.
13. Zafar K.S., Siegel D., Ross D. A potential role for cyclized quinones derived from dopamine DOPA and 34-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 2006, 70:1079-1086.
14. Zhou Z.D., Lim T.M. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinines. Free Radic. Res. 2009, 43:417-430.
15. Paris I., Perez-Pastene C., Cardenas S., Iturriaga-Vasquez P., Muñoz P., Couve E., Caviedes P., Segura-Aguilar J. Aminochrome induces disruption of actin alpha- and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. J. Neurotox. Res. 2010, 18:82-92.
16. Arriagada C., Paris I., Sanchez de las Matas M.J., Martinez-Alvarado P., Cardenas S., Castaneda P., Graumann R., Perez-Pastene C., Olea-Azar C., Couve E., Herrero M.T., Caviedes P., Segura-Aguilar J. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis and hydroxyl radical formation. Neurobiol. Dis. 2004, 16:468-477.
17. Fon E.A., Pothos E.N., Sun B.C., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997, 19:1271-1283.
18. Taylor T.N., Caudle W.M., Miller G.W. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011, 2011:124-165.
19. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11869-11874.
20. Liang C.L., Nelson O., Yazdani U., Pasbakhsh P., German D.C. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neuron. J. Comp. Neurol. 2004, 473:97-106.
21. 3+ induce neurotoxicity of dopamine: prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase. Chem. Biol. Interact. 1989, 72:309-324.
22. Lozano J., Muñoz P., Nore B.F., Ledoux S., Segura-Aguilar J. Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chem. Res. Toxicol. 2010, 23:1492-1496.
23. Paris I., Muñoz P., Huenchuguala S., Couve E., Sanders L.H., Greenamyre J.T., Caviedes P., Segura-Aguilar J. Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol. Sci. 2011, 121:376-388.
24. Fuentes P., Paris I., Nassif M., Caviedes P., Segura-Aguilar J. Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia Nigra-derived cell line-an experimental cell model for dopamine toxicity studies. Chem. Res. Toxicol. 2007, 20:776-783.
25. Cardenas S.P., Perez-Pastene C., Couve E., Segura-Aguilar J. The DT-diaphorase prevents the aggregation of a-synuclein induced by aminochrome. Neurotox. Res. 2008, 13:136.
26. Segura-Aguilar J., Cardenas S., Riveros A., Fuentes-Bravo P., Lozano J., Graumann R., Paris I., Nassif M., Caviedes I. DT-Diaphorase prevents the formation of alpha-synuclein adducts with aminochrome. Soc. Neurosci. Abstr. 2006, 824:17.
27. Paris I., Dagnino-Subiabre A., Marcelain K., Bennett L.B., Caviedes P., Caviedes R., Olea-Azar C., Segura-Aguilar J. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J. Neurochem. 2001, 77:519-529.
28. Dagnino-Subiabre A., Marcelain K., Arriagada C., Paris I., Caviedes P., Caviedes R., Segura-Aguilar J. Mol. Cell. Biochem. 2000, 212:131-134.
29. Segura-Aguilar J., Kaiser R., Lind C. Separation and characterization of isoforms of DT-diaphorase from rat liver cytosol. Biochim. Biophys. Acta 1992, 1120:33-42.
30. Ayala-Torres S., Chen Y., Svoboda T., Rosenblatt J., Van Houten B. Analysis of gene-specific DNA damage and repair using quantitative polymerase chain reaction. Methods 2000, 22:135-147.
31. Santos J.H., Meyer J.N., Mandavilli B.S., Van Houten B. Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. Methods Mol. Biol. 2006, 314:183-199.
32. Williams A. MPTP parkinsonism. Br. Med. J. 1984, 289:1401-1402.
33. Zhang W., Phillips K., Wielgus A.R., Liu J., Albertini A., Zucca F.A., Faust R., Qian S.Y., Miller D.S., Chignell C.F., Wilson B., Jackson-Lewis V., Przedborski S., Joset D., Loike J., Hong J.S., Sulzer D., Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 2011, 19:63-72.
34. Zecca L., Wilms H., Geick S., Claasen J.H., Brandenburg L.O., Holzknecht C., Panizza M.L., Zucca F.A., Deuschl G., Sievers J., Lucius R. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008, 116:47-55.
35. LaVoie M.J., Ostaszewski B.L., Weihofen Schlossmacher A., Selkoc D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11:1159-1161.
36. Xu Y., Stokes A.H., Roskoski R., Vrana K. Dopamine in the presence of tyrosinase covalently modifies and inactivates tyrosinase hydroxylase. J. Neurosci. Res. 1998, 54:691-697.
37. Whitehead R., Ferrer J.V., Javitch J.A., Justice J.B. Reaction of oxidized dopamine whit endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 2001, 76:1242-1251.
38. Paris I., Cárdenas S., Lozano J., Perez-Pastene C., Graumann R., Caviedes P., Segura-Aguilar J. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease. Neurotox. Res. 2007, 13:221-230.
39. Cartier E.A., Parra L.A., Baust T.B., Quiroz M., Salazar G., Faundez V., Egaña L., Torres G.E. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J. Biol. Chem. 2010, 15:1957-1966.
40. Chen J.J., Wilkinson J.R. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?. J. Clin. Pharmacol. May 31 2011, [Electronic publication ahead of print]. 10.1177/0091270011406279.
41. Baez S., Linderson Y., Segura-Aguilar J. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPH-cytochrome P-450 reductase. Biochem. Mol. Med. 1995, 54:12-18.
42. Segura-Aguilar J., Metodiewa D., Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cyytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1998, 1381:1-6.
43. Matsui Y., Kyoi S., Takagi H., Hsu C.P., Hariharan N., Ago T., Vatner S.F., Sadoshima J. Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy 2008, 4:409-415.
44. Tettamanti G., Saló E., González-Estévez C., Felix D.A., Grimaldi A., de Eguileor M. Autophagy in invertebrates: insights into development, regeneration and body remodeling. Curr. Pharm. Des. 2008, 14:116-125.
45. Kuma A., Mizushima N. Physiological role of autophagy as an intracellular recycling system: with an emphasis on nutrient metabolism. Semin. Cell Dev. Biol. 2010, 21:683-690.
46. Seglen P.O., Brinchmann M.F. Purification of autophagosomes from rat hepatocytes. Autophagy 2010, 6:542-547.
47. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
48. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 2007, 27:8138-8148.
49. Vergo S., Johansen J.L., Leist M., Lotharius J. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 2007, 1185:18-32.
50. Guillot T.S., Shepherd K.R., Richardson J.R., Wang M.Z., Li Y., Emson P.C., Miller G.W. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J. Neurochem. 2008, 106:2205-2217.
51. Nakagawa T., Suzuki Y., Nagayasu K., Kitaichi M., Shirakawa H., Kaneko S. Repeated exposure to methamphetamine, cocaine or morphine induces augmentation of dopamine release in rat mesocorticolimbic slice co-cultures. PLoS One 2011, 6:24865.
52. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 1998, 70:1973-1978.
53. Adam Y., Edwards R.H., Schuldiner S. Expression and function of the rat vesicular monoamine transporter 2. Am. J. Physiol. Cell Physiol. 2008, 294:C1004-C1011.
54. Scherman D., Henry J.P. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 1984, 25:113-122.
55. 3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J. Neurochem. 1998, 71:258-265.